Quick Answer
NovoCure Ltd reported Cash And Cash Equivalents At Carrying Value of $93.55 million for the year ending 2025.
- NovoCure Ltd showed a decrease of -42.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from NovoCure Ltd's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), NovoCure Ltd's Cash And Cash Equivalents At Carrying Value has grown by 168.1%.
- Historical annual values: Fiscal year 2025: $93.55 million | Fiscal year 2024: $163.77 million | Fiscal year 2023: $240.82 million | Fiscal year 2022: $115.33 million | Fiscal year 2021: $208.80 million | Fiscal year 2020: $234.67 million | Fiscal year 2019: $177.32 million | Fiscal year 2018: $140.62 million | Fiscal year 2017: $78.59 million | Fiscal year 2016: $99.78 million | Fiscal year 2015: $119.42 million | Fiscal year 2014: $57.61 million | Fiscal year 2013: $175.89 million | Fiscal year 2012: $34.89 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: